MCC950 trial

[janers]

Anyone familiar with this molecule referenced in the article below, seems like a promising trial is underway out of the University of Queensland. Any news?

thenewdaily.com.au/life/wel...

[WinnieThePoo]

We've seen it. There are several posts about it - usually hyped a "Stops Parkinsons in its tracks"

It's good to see a phase 1 trial in humans appears to be under way with Phase 2 planned for 2020, if phase 1 shows it safe enough (which seems near certain)

Phase 2 is likely to take at least 3 years (2023?)

Usually there would then be a phase 3 which from end of phase 2 to results is rarely less than 5 years

Promising. Good to see human trials. May be a while yet

[park_bear]

"A new therapy that appears to stop Parkinson’s disease “in its tracks” will begin phase-one clinical trials in humans next year."

This means it has not yet been tested in humans for safety or efficacy when it comes to Parkinson's. Only a tiny fraction of candidate drugs make it from preclinical through 3 phases of testing and then approval. For those that do the process takes many years.

Also, the mouse model that is typically used to test candidate Parkinson's drugs is an artificially induced parkinsonism which is not the same thing as Parkinson's disease. Substances that are good for treating the former are not necessarily good for treating the latter.

[jeffreyn]

Inflazome have very recently posted a new project record (NLRP3 Inhibition) on the Clinical Trials website:

clinicaltrials.gov/ct2/show...

[sharoncrayn]

Haven't even begun to recruit participants, which probably means they have yet to finalize the design and parameters. We have to assume their primary interest in testing their drug Inzomrelid is whether or not it causes adverse effects in healthy participants.

Does that mean PD patients with obvious problems be excluded? I would assume so.

[jeffreyn in reply to sharoncrayn]

From thenewdaily article linked to by janers:

"The phase-one tests next year [2019] will determine whether or not the drug is safe in healthy people. All going well, volunteers with Parkinson’s will be recruited for phase-two testing in 2020."

[sharoncrayn in reply to jeffreyn]

I read the specifications in the actual clinical trial application.

[Rhyothemis]

Experimental studies show MCC950 could be effective in treating not just PD and MSA but also AD and spinal cord injuries.

"The biggest hurdle, apart from funding, is that MCC950 came off a

patent. This means the researchers have had to develop variations of the

original drug for intellectual property reasons. Those new drugs are

currently being tested and, according to Dr Woodruff, proving to be even

more effective."

So they won't be trialing MCC950 since they can't make big bucks off of it, they instead had to make a derivative to trial. It's infuriating. I wonder why countries with nationalized health care systems don't do clinical trials on things off-patent/not patentable - you would think it would be in their interest.

Inflazome's drug is IZD174 aka inzomelid. It has completed a safety and tolerability trial and there is a pending trial for PD:

clinicaltrials.gov/ct2/resu...

Inflazome was recently (Sept 2020) purchased by Roche; I guess that's a good sign.

inflazome.com/press-release...